.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Chinese Patent Office
Accenture
Dow
Citi
Healthtrust
Teva
Federal Trade Commission
QuintilesIMS
Moodys

Generated: July 22, 2017

DrugPatentWatch Database Preview

URSO 250 Drug Profile

« Back to Dashboard

What is the patent landscape for Urso 250, and when can generic versions of Urso 250 launch?

Urso 250 is a drug marketed by Forest Labs Inc and is included in one NDA.

The generic ingredient in URSO 250 is ursodiol. There are six drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the ursodiol profile page.

Summary for Tradename: URSO 250

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list4
Bulk Api Vendors: see list48
Clinical Trials: see list1,319
Patent Applications: see list3,614
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:URSO 250 at DailyMed

Pharmacology for Tradename: URSO 250

Ingredient-typeBile Acids and Salts
Drug ClassBile Acid
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Forest Labs Inc
URSO 250
ursodiol
TABLET;ORAL020675-001Dec 10, 1997ABRXYesNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: URSO 250

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Forest Labs Inc
URSO 250
ursodiol
TABLET;ORAL020675-001Dec 10, 19974,859,660► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Queensland Health
Federal Trade Commission
Dow
Covington
Harvard Business School
Daiichi Sankyo
AstraZeneca
Accenture
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot